

COVID-19 Antigen Home Test

A rapid test for the detection of SARS-CoV-2 antigens in anterior nasal specimens directly from individuals within 7 days of symptom onset or without symptoms or other epidemiological reasons to suspect COVID-19 infection.

ORDER C-FFC-19 TODAY

Call 877-561-0500 to purchase your own home test.



Fast



Easy to Use



Accurate

Flowflex COVID-19 Antigen Home Test

Qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nasal swab specimens directly from individuals within 7 days of symptom onset or without symptoms or other epidemiological reasons to suspect COVID-19 infection. This test is authorized for non-prescription home use with self-collected anterior nasal swab specimens directly from individuals aged 14 years and older or with adult-collected anterior nasal samples directly from individuals aged 2 years or older. **The Flowflex COVID-19 Antigen Home Test does not require serial testing.**

- Anterior nasal swab specimens
- Results in 15 minutes
- 12 Months shelf life
- Store between 36 to 86° F
- Sample self-collection ages 14 and older
- Sample collection by an adult in **children ages 2 to 13**
- Excellent performance when compared to an FDA authorized molecular SARS-CoV-2 test.

Clinical Performance

The performance of Flowflex COVID-19 Antigen Home Test was established in an all-comers clinical study conducted between March 2021 and May 2021 with 172 nasal swabs self-collected or pair-collected by another study participant from 108 individual symptomatic patients (within 7 days of onset) suspected of COVID-19 and 64 asymptomatic patients. The Flowflex COVID-19 Antigen Home Test results were compared to an FDA EUA RT-PCR COVID-19 assay to determine test performance in the table below:

Performance of Flowflex COVID-19 Antigen Home Test in ALL subjects

| Flowflex COVID-19 Antigen Home Test | RT-PCR method | | |
|---|----------------------------------|----------|-------|
| | Positive | Negative | Total |
| Positive | 39 | 0 | 39 |
| Negative | 3 | 130 | 133 |
| Total | 42 | 130 | 172 |
| Positive Percent Agreement (PPA) | 93% (95% CI: 81% - 99%) | | |
| Negative Percent Agreement (NPA) | 100% (95% CI: 97% - 100%) | | |

Analytical Sensitivity: Limit of Detection (LoD) :


LoD was determined as the lowest virus concentration that was detected $\geq 95\%$ of the time. Based on this testing, the LoD in nasal matrix was confirmed to be 2.5×10^3 TCID₅₀/mL

| SARS-CoV-2 Concentration in nasal matrix | Number of Positives/Total | % Detected |
|--|---------------------------|------------|
| 2.5×10^3 TCID ₅₀ /mL | 60/60 | 100% |

Materials Provided

- Test Cassette(s)
- Package Insert
- Extraction Buffer Tube(s)
- Nasal Swab(s)
- External Tube Holder - Package of 25 tests

Test Procedure and Interpretation



Ordering Information

| Product Name | Catalog No. | Format | Specimen | Package |
|---------------------------------------|-------------|----------|-------------|--------------|
| Flowflex COVID - 19 antigen Home Test | L031-118B5 | Cassette | Nasal swabs | 1 Test/Kit |
| Flowflex COVID - 19 antigen Home Test | L031-125M5 | Cassette | Nasal Swabs | 2 Tests/Kit |
| Flowflex COVID - 19 antigen Home Test | L031-125N5 | Cassette | Nasal swabs | 5 Tests/Kit |
| Flowflex COVID - 19 antigen Home Test | L031-125P5 | Cassette | Nasal Swabs | 25 Tests/Kit |

- This product has not been FDA cleared or approved but has been authorized by FDA under an EUA.
- This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
- For more information on EUAs please visit: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>
- For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19
- For detailed instructions, please visit: www.aconlabs.com



39 Western Hwy.
West Nyack, NY 10994
www.DuralineSystems.com
877-561-0500